Quintrio
Home

Stock overview

Regencell Bioscience Holdings Limited Ordinary Shares

RGC

Regencell Bioscience Holdings Ltd is an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Its goal is to save and improve the lives of patients, their families and caregivers and become a market leader for the natural and holistic treatment globally. The company operates and manages its business as a single segment - in the research and development of the company's product candidates.

Last trade $4.62
Day change -$0.10 (-2.12%)
Day range $4.36 – $4.89
Volume 72,908
Market cap $2.34B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for RGC.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for RGC.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Class action lawsuits have been filed against LKQ Corporation, Regencell Bioscience Holdings Limited, and Globant S.A. The complaints allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their businesses. LKQ faced issues with FinishMaster losing major customers post-acquisition, Regencell was vulnerable to market manipulation, and Globant faced decreasing demand in Latin America with frozen wages.

GlobeNewswire Inc.

FSK DEADLINE NOTICE: ROSEN, A RANKED AND LEADING FIRM, Encourages FS KKR Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FSK

Rosen Law Firm has announced securities class action lawsuits against FS KKR Capital Corp. (FSK), Regencell Bioscience Holdings Limited (RGC), and Microsoft (MSFT). The FSK lawsuit alleges the company made false statements regarding portfolio restructuring effectiveness, investment valuations, and distribution strategy durability. Investors with losses exceeding $100K are encouraged to join the class action before the July 6, 2026 deadline for FSK and June 23, 2026 for RGC.

GlobeNewswire Inc.

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market manipulation vulnerabilities and regulatory risks.

GlobeNewswire Inc.

RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

Faruqi & Faruqi, LLP is reminding investors in Regencell Bioscience Holdings Limited (RGC) of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Regencell and its executives made false and misleading statements by concealing the company's vulnerability to market manipulation and the resulting regulatory risks. The DOJ investigation was disclosed on October 31, 2025, causing RGC's share price to fall 18.56% on November 3, 2025.

GlobeNewswire Inc.

SRAD IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sportradar Group AG Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SRAD

Rosen Law Firm has issued multiple securities class action deadline alerts for investors. The primary case involves Sportradar Group AG (SRAD), where investors who purchased shares between November 7, 2024 and April 21, 2026 may be entitled to compensation. The lawsuit alleges that Sportradar made false statements about compliance and worked with black-market gambling operators while claiming strict regulatory adherence. The lead plaintiff deadline is July 17, 2026. Similar deadline alerts were also issued for FS KKR Capital Corp. (FSK) and Regencell Bioscience Holdings Limited (RGC).

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Feb 15, 2018$0.0058Feb 26, 2018recurring
Dec 1, 2017$0.0058Dec 15, 2017recurring
Aug 31, 2017$0.0058Sep 15, 2017recurring
Jun 1, 2017$0.0058Jun 15, 2017recurring
Mar 1, 2017$0.0058Mar 15, 2017recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 16, 202538-for-1forward split